# AML-17 (NCT00052299)

> Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00052299
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- Conditions: Leukemia
- Interventions: cytarabine; etoposide; gemtuzumab ozogamicin; idarubicin; mitoxantrone hydrochloride
- Enrollment: 472
- Primary outcome: Overall survival

## Commentary we found

- Podcasts: 11
- X threads: 5
- YouTube: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=aml-17-nct00052299

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00052299", "email": "<work email>"}; the inbox owner confirms by the emailed link.